ArticleTargeted oncology2026
Association of TP53 Truncating Mutations with Time to Treatment Failure after First-Line Chemoimmunotherapy in HER2-Mutant Non-Small Cell Lung Cancer.
Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiomarkers associated with first-line chemoimmunotherapy outcomes in HER2-mutant non-small cell lung cancer (NSCLC) remain incompletely characterized.
objectiveTo evaluate whether TP53 truncating mutations are associated with clinical outcomes after first-line pembrolizumab plus pemetrexed-platinum in patients with HER2-mutant NSCLC. PATIENTS AND
methodsWe conducted a retrospective clinicogenomic study using the nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database. Patients with advanced or recurrent HER2-mutant NSCLC who received first-line pembrolizumab plus pemetrexed-platinum were included. The primary endpoint was time to treatment failure (TTF).
resultsAmong 69 patients, 21 (30.4%) harbored TP53 truncating mutations. Patients with TP53 truncating mutations had shorter TTF than those without TP53 truncating mutations (median, 6.0 versus 7.6 months; hazard ratio [HR], 1.97; 95% confidence interval [CI] 1.11-3.49; log-rank P = 0.018). The 9-month TTF rates were 4.8% and 40.6%, respectively. After adjustment for age, Eastern Cooperative Oncology Group performance status, and programmed death-ligand 1 tumor proportion score, TP53 truncating mutations remained associated with shorter TTF (HR, 1.98; 95% CI 1.08-3.63; P = 0.026). No significant differences were observed in overall survival or objective response rate.
conclusionsTP53 truncating mutations were associated with shorter TTF during first-line pembrolizumab plus pemetrexed-platinum in HER2-mutant NSCLC, without significant differences in overall survival or objective response rate. These findings suggest a potential association with shorter treatment durability and require validation in independent cohorts.
Identifiers
42891904What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.